secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-08-22T23:59:59+00:00
Accession:  0001104659-24-091806
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia sues FDA over Tyvaso DPI exclusivity blocking YUTREPIA approval
------------------------------------------------------------------------

- FDA granted tentative approval of YUTREPIA on Aug 16, 2024, but final approval delayed until after May 23, 2025.
- Liquidia filed suit in D.C. District Court (Case No. 1:24-cv-02428) challenging FDA's 3-year NCI exclusivity for Tyvaso DPI.
- United Therapeutics voluntarily dismissed its complaint challenging FDA's acceptance of Liquidia's amended NDA on Aug 20.
- Liquidia argues FDA's decision violates congressional intent and seeks to vacate exclusivity to allow timely market entry.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924091806/0001104659-24-091806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924091806/tm2422418d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-091806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer